Genio Implant vs Inspire 2026: Hypoglossal Stimulation Comparison

Hypoglossal nerve stimulation has reshaped the surgical landscape for moderate-to-severe obstructive sleep apnoea (OSA) in adults who cannot tolerate CPAP. Two devices dominate the market in Europe in 2026: Genio, made by Belgian company Nyxoah, and Inspire, made by Inspire Medical Systems. Both stimulate the hypoglossal nerve to keep the airway open, but they differ in design, surgery, EU price, MRI compatibility, and candidate criteria. This guide compares them head to head for European patients. For background on alternatives, see our Inspire vs nasal dilator comparison.

The short version: Inspire is the more established option with longer follow-up data. Genio is the newer, battery-free, EU-engineered design that simplifies the surgery and offers full-body MRI compatibility. Both are CE-marked, both have produced clinically meaningful AHI reductions, and the right choice depends on your anatomy, surgical risk, and what your EU sleep clinic offers. For a wider context on options, also see our overview of CPAP alternatives ranked by evidence.

How hypoglossal nerve stimulation works

The hypoglossal nerve controls the tongue. During obstructive apnoea, the tongue can fall back and block the airway. A hypoglossal nerve stimulator delivers a mild pulse to the nerve, contracting the tongue muscles forward and opening the airway. The pulse is timed to inspiration so it works synchronously with breathing.

The therapy is reserved for adults with moderate-to-severe OSA (AHI 15 to 65) who cannot tolerate CPAP, are not severely obese, and have favourable upper-airway anatomy confirmed by drug-induced sleep endoscopy (DISE). The European Sleep Research Society and national societies including DGSM (Germany) and SFRMS (France) endorse hypoglossal stimulation for this specific population.

Genio (Nyxoah): the EU-engineered, battery-free option

Nyxoah is a Belgian medical-device company headquartered in Mont-Saint-Guibert. Genio is its flagship hypoglossal stimulation system. The implant has no battery and no chest pulse generator. Stimulation is powered externally by a small disposable patch worn under the chin at night that wirelessly transmits energy to a small implanted electrode. This eliminates the chest pocket implant and the eventual battery-replacement surgery that other systems require.

Genio received the CE mark in 2019. The US FDA cleared it in August 2024. EU clinical use spans Belgium, Germany, France, Italy, Spain, the Netherlands, Austria, and several Nordic countries through specialised sleep surgery centres. Surgical implantation is single-stage and outpatient at most EU centres. The disposable activation chip is replaced periodically. Genio offers full-body 1.5T and 3T MRI compatibility — important for patients who anticipate spinal, brain, or cardiac imaging.

Genio key data points

• Trial. BETTER SLEEP study, published in 2023 in The Lancet Digital Health.
• Effect. 24-month responder rate (≥50% AHI reduction with AHI<20) of around 64 percent.
• Adherence. 5+ nights per week reported in around 80 percent of users.
• MRI. Full-body 1.5T and 3T conditional.
• Surgery. Single submental incision, outpatient.

Inspire: the established gold standard with longer follow-up

Inspire Medical Systems, headquartered in Minnesota, manufactures the Inspire upper-airway stimulator. The device is implanted in three sites: a small pulse generator in the upper chest, a sensor lead between the ribs to detect breathing, and a stimulator lead at the hypoglossal nerve. CE-marked since 2010 and US FDA-approved since 2014. Used in EU centres for over a decade.

The user activates the device with a small remote at bedtime. Battery life is around 11 years; replacement requires a brief outpatient procedure. The longest follow-up data is from the STAR trial, with 5-year published results showing around 70 percent of patients meeting responder criteria. Inspire is widely available in EU sleep surgery centres in Germany, the Netherlands, France, Italy, Spain, the UK, and Belgium.

Inspire key data points

• Trial. STAR study, with 5-year follow-up published in JAMA Otolaryngology.
• Effect. 5-year responder rate around 70 percent. Mean AHI reduction around 60 to 70 percent.
• Adherence. 6+ nights per week reported in around 85 percent of users.
• MRI. 1.5T head-only conditional. Full-body MRI restricted.
• Surgery. Three incisions: chest, lateral rib, submental. Inpatient or extended outpatient.

Genio vs Inspire: head-to-head comparison

Effect over time: what the evidence shows at 5+ years

The Inspire STAR trial 5-year follow-up published in JAMA Otolaryngology – Head & Neck Surgery showed sustained AHI reduction and quality-of-life improvement at year 5. Around 70 percent of patients still met responder criteria, defined as ≥50 percent AHI reduction with absolute AHI under 20. Adverse events at long term were rare. Battery longevity matched expectations at roughly 11 years.

Genio's BETTER SLEEP trial 24-month follow-up reported similar response patterns to Inspire's 24-month equivalent: roughly 60 to 70 percent of patients maintained responder status. Longer-term Genio data is still accumulating in the EU registry. As of 2026, the published evidence on Genio extends to roughly 36 months, with promising stability of effect. Both manufacturers maintain post-marketing surveillance through their EU registries.

What to ask your sleep specialist before deciding

• Has your DISE confirmed the obstruction pattern is suitable for hypoglossal stimulation?
• What is the response rate for patients of your age and BMI in your local centre?
• What is the expected post-op follow-up frequency at this centre?
• Will the cost be funded fully, partially, or out of pocket in your specific national context?
• What is the realistic surgery waiting list at the centre?

EU funding and access in 2026

Hypoglossal stimulation funding varies dramatically across Europe. In Germany, GKV/PKV cover Inspire and Genio for diagnosed moderate-severe OSA when CPAP has failed; G-BA decisions guide reimbursement. The Netherlands funds both via Zorgverzekering for confirmed candidates. France funds via Sécurité Sociale for diagnosed cases meeting strict criteria, with growing coverage of Genio after positive HAS opinions. The UK NHS covers Inspire selectively in specialist centres; Genio access is more limited.

Italy SSN, Spain Seguridad Social, and Belgian INAMI provide partial coverage in tertiary centres on a case-by-case basis. Many adults still pay partial out-of-pocket fees of €5,000 to €15,000 even when funded. Private routes (€20,000 to €35,000) shorten waiting lists in countries with backlogs.

Who is a candidate?

Both devices share core eligibility: diagnosed moderate-to-severe OSA (AHI 15 to 65), failure or intolerance of CPAP, BMI under approximately 32, age 18+ (Genio includes adolescents in Europe in some indications), and DISE confirming the right pattern of airway collapse. Concentric collapse at the soft palate is a common exclusion for Inspire; Genio's design tolerates a wider range of collapse patterns.

Who is not a candidate

• Severe obesity (BMI > 32) until weight reduced.
• Central sleep apnoea or mixed apnoea with high central index.
• Significant cardiac arrhythmia precluding nerve stimulation.
• Pregnant women and patients planning pregnancy in 12 months.
• Active head and neck cancer or major cervical spine pathology.

How candidacy is established: the DISE pathway

Both Genio and Inspire require drug-induced sleep endoscopy (DISE) before implantation. DISE is a short procedure under sedation in which the ENT surgeon visualises the upper airway with a thin endoscope as the patient transitions toward natural-like sleep. The exam reveals where the airway collapses: soft palate, lateral pharyngeal walls, tongue base, or epiglottis. The collapse pattern, especially the orientation of soft palate collapse (anteroposterior versus concentric), determines candidacy.

Inspire historically excluded patients with complete concentric collapse (CCC) at the soft palate because the device's stimulation pattern is less effective in that geometry. Genio's bilateral activation chip and broader electrode contact give it more flexibility for CCC and mixed patterns. Some EU centres specialise in DISE workups for hypoglossal stimulation candidates and have shorter waiting lists than general sleep services.

Time from referral to surgery

EU waiting lists vary by country and centre. Typical timelines: 3 to 6 months from initial sleep medicine consultation to DISE, then a further 2 to 4 months from DISE to surgery for funded pathways. Private routes can compress this to 4 to 8 weeks total but at full out-of-pocket cost.

Why a Belgian battery-free design matters

Genio's design philosophy reflects two decades of EU medical device engineering culture: minimise implanted hardware, simplify the surgical pathway, and design for long-term MRI safety. Removing the battery is not a cosmetic choice — it eliminates a planned re-operation around year 11 and removes the need for a chest-pocket implant that can occasionally migrate or cause discomfort. For younger patients facing a 30 to 40 year horizon with the device, the cumulative reduction in surgical exposure is meaningful.

The trade-off is the activation chip on the chin, which the patient applies before sleep and removes in the morning. Some users find this an extra step; others prefer it because the implant can be fully "off" during the day with no internal stimulation activity. Long-term EU registry data is still maturing on adherence and patient preference between Genio and Inspire designs. Both manufacturers offer device-tracking apps for users.

What the surgery and recovery look like

Both Genio and Inspire are implanted under general anaesthesia. Genio is generally a single-site outpatient procedure: a small submental incision under the chin to place the electrode against the hypoglossal nerve. Patients typically go home the same day. Recovery is 2 to 4 weeks of soft swelling, mild tongue stiffness, and gradual settling. The first device activation usually occurs 4 to 6 weeks after implantation to allow tissue healing.

Inspire involves three incisions — chest pocket for the pulse generator, lateral chest for a respiratory sensor lead, and submental for the stimulator lead — typically over a 90 to 120 minute procedure. Most patients are discharged the same day or after a single overnight stay. Recovery is similar: 2 to 4 weeks. Initial activation is typically 4 to 6 weeks post-op. Both devices then enter a titration period over 1 to 3 months to find the optimal stimulation amplitude.

Long-term follow-up

EU patients with Inspire typically attend annual sleep medicine follow-up to recheck device performance with a home sleep test or polysomnography. Battery replacement on Inspire happens around year 11 as a brief outpatient procedure under local anaesthesia. Genio has no battery to replace; the disposable activation chip on the chin patch is replaced periodically and is not surgical. Both manufacturers maintain EU patient registries to track long-term safety.

If you are not a hypoglossal stimulation candidate

Most snorers and most adults with mild OSA are not candidates for either implant. The good news is the alternative ladder is rich. CPAP for moderate-severe OSA. Mandibular advancement devices for tongue-base OSA where you can tolerate dental hardware. Positional therapy if you snore mainly on your back. Weight-loss drugs (Wegovy, Mounjaro / Zepbound) where BMI exceeds 30. And for nasal-collapse snoring or mild-to-moderate OSA, the €39 Back2Sleep starter kit is the most accessible option in the EU — CE-certified, no prescription, ships across Europe. It is not a CPAP replacement for severe disease but is a sensible first-line tool for the majority of snorers who never become implant candidates.

If you are unsure where you stand, the sleep risk screening takes a few minutes and helps frame next steps. Severe symptoms always need a proper sleep study — at home in most EU countries, or in-lab if recommended by your physician. For broader perspective on choosing among the options, see our anti-snoring device comparison.

Frequently asked questions

Frequently Asked Questions